公开(公告)号：US11952382B1

公开(公告)日：2024-04-09

申请号：US18387550

申请日：2023-11-07

申请人： KING FAISAL UNIVERSITY

发明人： Hany Mohamed Abd El-Lateef Ahmed ,  Mai Mostafa Khalaf Ali ,  Antar Ahmed Abdelhamid Ahmed

IPC分类号： A61P31/04 ,  A61K31/4353 ,  A61P31/10 ,  C07D491/044

CPC分类号： C07D491/044 ,  A61P31/04 ,  A61P31/10

摘要： An 2-benzo-[3,4-b]quinolino-[b,g]indeno[1′,2′:3,4]fluoreno-[1,2-d]oxonine-24-flouro-5,11,16,21-tetraone compound, its synthesis, and its use as an antimicrobial agent.

公开(公告)号：US11945819B1

公开(公告)日：2024-04-02

申请号：US18371126

申请日：2023-09-21

申请人： KING FAISAL UNIVERSITY

发明人： Katharigatta N. Venugopala ,  Pran Kishore Deb ,  Pramod Patil ,  Osama I. Alwassil ,  Mohamed A. Morsy ,  Bandar Aldhubiab ,  Vijaykumar Uppar ,  Mahmoud Kandeel ,  Praveen B. Managutti ,  Basavaraj Padmashali

IPC分类号： A61K31/4353 ,  A61P29/00 ,  C07D471/04 ,  C07D471/16

CPC分类号： C07D471/04 ,  A61P29/00 ,  C07B2200/13

摘要： Novel dimethyl 7-bromo-1-(4-substituted benzoyl)pyrrolo[1,2-α]quinoline-2,3-dicarboxylates compounds, having the structure:




A method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The dimethyl 7-bromo-1-(4-substituted benzoyl)pyrrolo[1,2-α]quinoline-2,3-dicarboxylates compounds, identified as anti-inflammatory agents, are useful for treating inflammation, pain, and swelling in a patient.

公开(公告)号：US11708364B2

公开(公告)日：2023-07-25

申请号：US17216114

申请日：2021-03-29

申请人： AGV Discovery ,  Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Centre National de la Recherche Scientifique (CNRS) ,  Universite De Montpellier

发明人： Jean-François Guichou ,  Cédric Bories ,  Clément Geoffroy ,  Charline Duquenne ,  Muriel Gelin ,  Gilles Labesse ,  Yannick Bessin ,  Loic Mathieu

IPC分类号： A61K31/4353 ,  C07D471/04 ,  A61P35/00 ,  C07D519/00 ,  C07F9/6561 ,  C07D491/048 ,  C07D491/113 ,  C07D491/107

CPC分类号： C07D471/04 ,  A61K31/4353 ,  A61P35/00 ,  C07D491/048 ,  C07D491/107 ,  C07D491/113 ,  C07D519/00 ,  C07F9/6561

摘要： The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.

公开(公告)号：US11642335B2

公开(公告)日：2023-05-09

申请号：US17034228

申请日：2020-09-28

申请人： Board of Regents, The University of Texas System

发明人： Yaoqiu Zhu

IPC分类号： C07D211/96 ,  A61K31/45 ,  A61K31/4353

CPC分类号： A61K31/45 ,  C07D211/96 ,  A61K31/4353

摘要： A method of synthesizing a clopidogrel metabolite is provided. A piperidone intermediate is formed from a mandelate. An asymmetric ketone reduction of the piperidone intermediate is performed. A mercapto installation is performed on the piperidone intermediate to form a clopidogrel metabolite that includes a 4-carbon chiral center having an (R) configuration.

公开(公告)号：US20230066830A1

公开(公告)日：2023-03-02

申请号：US17787483

申请日：2020-12-18

申请人： VIRGINIA COMMONWEALTH UNIVERSITY

发明人： Paul B. FISHER ,  Sarmistha TALUKDAR ,  Swadesh K. DAS ,  Anjan PRADHAN ,  Luni EMDAD

IPC分类号： A61K31/519 ,  C12N15/113 ,  A61K31/337 ,  A61K31/439 ,  A61K31/165 ,  A61K31/18 ,  A61K31/4353 ,  A61K38/15 ,  A61K31/336 ,  A61K31/167 ,  A61K31/4406

摘要： Provided herein are pharmaceutical compositions and methods useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

公开(公告)号：US20230055657A1

公开(公告)日：2023-02-23

申请号：US17786499

申请日：2020-12-18

申请人： NOVARTIS AG ,  PLIANT THERAPEUTICS, INC.

发明人： Kraig ANDERSON ,  Christopher BAILEY ,  Avirup BOSE ,  Jacob CHA ,  Nicole COOPER ,  Darren FINKELSTEIN ,  Linda GREENBAUM ,  Johannes HULL ,  Susan Caroline KIRKLAND ,  Katerina LEFTHERIS ,  Maureen REILLY ,  Peter TARSA ,  Chinweike UKOMADU

IPC分类号： A61K31/46 ,  A61K31/4353 ,  A61P1/16

摘要： The invention provides a pharmaceutical combination including an αvβ1 integrin inhibitor and at least one additional therapeutic agent for preventing, delaying or treating liver diseases or disorders. The at least one additional therapeutic agent may be a farnesoid X receptor (FXR) agonist. For example, the pharmaceutical combination includes (S)-2-(4-methyltetrahydro-2H-pyran-4-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid (Compound 1) and 2-[3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1, 3-ben-zothiazole-6-carboxylic acid (tropifexor).

公开(公告)号：US11458122B2

公开(公告)日：2022-10-04

申请号：US16637295

申请日：2018-08-08

申请人： CHILDREN'S HOSPITAL MEDICAL CENTER

发明人： Xuelian He ,  Qing Lu ,  Liguo Zhang

IPC分类号： A61K31/415 ,  A61P25/28 ,  A61K9/00 ,  A61K31/167 ,  A61K31/4353 ,  A61K45/06

摘要： Some embodiments of the invention include methods for treating an animal for disease or nerve damage, comprising administration of a composition comprising a myelination enhancing inhibitor to the animal. Other embodiments of the invention include methods for treating an animal for disease or nerve damage, comprising administration of a composition comprising an HDAC3 inhibitor to the animal. Still other embodiments of the invention include methods for treating an animal for MS or nerve damage, comprising administration of a composition comprising an HDAC3 inhibitor to the animal. Additional embodiments of the invention are also discussed herein.

公开(公告)号：US20220280484A1

公开(公告)日：2022-09-08

申请号：US17736576

申请日：2022-05-04

申请人： Imperial College Innovations Limited ,  United Kingdom Research and Innovation

发明人： Edward TATE ,  Wouter KALLEMEIJN ,  Jesus GIL ,  Domhnall MCHUGH

IPC分类号： A61K31/416 ,  A61P35/00 ,  A61K31/4353 ,  A61K31/496 ,  A61P11/00 ,  A61P1/16

摘要： The present invention provides a method of prophylaxis or treatment of a senescence-associated disease or disorder by administering to a subject in need thereof, a therapeutically effective amount of a NMT inhibitor.

公开(公告)号：US11351202B2

公开(公告)日：2022-06-07

申请号：US15849181

申请日：2017-12-20

申请人： ATHERSYS, INC. ,  AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.

发明人： Robert Mays ,  Robert J. Deans ,  David C. Hess ,  James E. Carroll ,  Cesar V. Borlongan

IPC分类号： A61K35/28 ,  A61K35/50 ,  A61K35/545 ,  A61K38/13 ,  A61K45/06 ,  C12N5/074 ,  A61K31/4353 ,  A61K31/436 ,  A61K31/485 ,  A61K31/52 ,  A61K31/661 ,  A61K35/12 ,  A61K35/30 ,  A61K35/407 ,  A61K35/44 ,  A61K35/48 ,  A61K35/51

摘要： The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.

公开(公告)号：US20220110982A1

公开(公告)日：2022-04-14

申请号：US17556330

申请日：2021-12-20

申请人： ABT Holding Company ,  AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.

发明人： Robert MAYS ,  Robert J. Deans ,  David C. Hess ,  James E. Carroll ,  Cesar V. Borlongan

IPC分类号： A61K35/50 ,  A61K31/661 ,  A61K38/13 ,  C12N5/074 ,  A61K31/52 ,  A61K35/51 ,  A61K35/407 ,  A61K35/48 ,  A61K31/485 ,  A61K35/28 ,  A61K35/44 ,  A61K35/30 ,  A61K45/06 ,  A61K31/436 ,  A61K35/12 ,  A61K31/4353 ,  A61K35/545

摘要： The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxis and that caused by insufficient blood supply. In some further particulars the invntion relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children, for example, and to the treatment of cortical infants and stroke with MAPCs in adults, for example.